ArticleScientific reports2025
Aloesin alleviates imiquimod-induced psoriasis in dermal layers through inhibition of interleukins and NF-κB signaling pathways.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Aloesin mitigates cisplatin-induced nephrotoxicity by suppressing NF-κB-mediated oxidative stress and modulating Bax/Bcl-2/caspase pathways.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Hibiscetin-Loaded Nanogel Ameliorated the Severity of IMQ-Induced Psoriasis-Like Inflammation in Mice via Down-Regulating Interleukins/TNF-α/NF-κB.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Aloesin is an aromatic chromone found in Aloe vera. Aloesin exhibits medicinal properties, including anti-inflammatory, anticancer, antioxidative, and antibacterial properties. Nonetheless, the possible therapeutic effects of aloesin on psoriasis have not yet been explored. The present study evaluated the impact of aloesin on psoriasis using an imiquimod (IMQ)-induced psoriasis model in mice. A standard drug group receiving methotrexate (MTX) was included to benchmark the efficacy of aloesin. The effects of aloesin on body weight, PASI, oxidative/anti-oxidative indexes, and histological alterations in skin tissue were estimated. Additionally, the inflammatory modulators interleukin (IL)-1β, IL-6, IL-17, IL-22, IL-23, tumor necrosis factor, nuclear factor kappa B (NF-κB), and transforming growth factor (TGF-β) were evaluated. Furthermore, oxidative stress parameters, including malondialdehyde (MDA), reactive oxygen species (ROS), superoxide dismutase (SOD), glutathione (GSH), and catalase (CAT), were assessed. Our findings revealed that both aloesin and MTX effectively reduced psoriasis area severity index (PASI) scores without any significant changes in the body weight of mice and ameliorated psoriatic lesions. Moreover, aloesin demonstrated effects comparable to those of MTX in several parameters and significantly downregulated the levels of immunomodulatory molecules, while increasing the levels of TGF-β. It efficiently up-regulated the levels of antioxidants (SOD, GSH, and CAT) and suppressed MDA as well as ROS activity. Our study demonstrated that aloesin had a significant effect on IMQ-induced psoriasis in mice, and the underlying mechanism may be the improvement of antioxidant and anti-inflammatory status, as well as the inhibition of NF-κB expression. MTX, as a standard comparator, allowed for direct benchmarking of aloesin anti-psoriatic effects. Psoriasis treatment could benefit from this approach in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.